全长间日疟原虫rPvs48/45蛋白制剂在BALB/c小鼠中的免疫原性
研究比较了在大肠杆菌和CHO细胞中表达的重组间日疟原虫Pvs48/45蛋白分别搭配Alhydrogel、GLA-SE和Montanide ISA-51三种佐剂共六种疫苗制剂在BALB/c小鼠中的免疫原性。小鼠于第0、20、40天免疫,结果显示六种制剂中三种诱导了体外传播阻断活性,其中CHO-rPvs48/45搭配Montanide ISA-51诱导的抗体反应最稳定、识别天然蛋白并产生最强的体外传播阻断活性。
要点
- 六种疫苗制剂中三种诱导了体外传播阻断活性。
- CHO-rPvs48/45搭配Montanide ISA-51诱导的抗体反应最稳定且体外传播阻断最强。
- CHO蛋白搭配Alhydrogel虽产生高初始抗体峰但抗体反应迅速减弱。
核心结论
- 六种疫苗制剂中三种诱导的抗体具有体外传播阻断活性。
- CHO-rPvs48/45搭配Montanide ISA-51制剂诱导的抗体反应最稳定、能识别天然蛋白并产生最强的体外传播阻断活性,结果鼓励进一步测试该蛋白的疫苗潜力。
研究设计与样本
- 在BALB/c小鼠中比较三种疫苗制剂的免疫原性,重组Pvs48/45蛋白分别在大肠杆菌和CHO细胞中表达、纯化后搭配Alhydrogel、GLA-SE和Montanide ISA-51佐剂。
- 动物于第0、20、40天免疫,采集血清用ELISA和免疫荧光试验(IFAT)分析特异性抗体反应。
- 另用直接膜饲喂试验(DMFA)评估血清对间日疟原虫配子体感染的人血在Anopheles albimanus蚊中的体外传播阻断活性(TRA)。
主要发现
- 多数免疫动物在首次免疫后血清阳转,部分动物在所有佐剂下抗体峰值达10^6。
- 三种佐剂制剂诱导的抗体反应和TRA效力不同。
- 两种蛋白的GLA-SE制剂诱导相似的抗体谱。
- Montanide ISA-51制剂中CHO-rPvs48/45比大肠杆菌制剂诱导更高且更持久的抗体滴度。
- CHO蛋白搭配Alhydrogel产生高初始抗体峰,但两种蛋白的抗体反应均迅速减弱;CHO-rPvs48/45搭配Montanide ISA-51诱导最有效的体外寄生虫阻断。
关键数值与推荐
- 部分动物抗体峰值达10^6(所有佐剂)。
- 六种疫苗制剂中三种诱导的抗体具有体外TRA。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pvs48/45 is a Plasmodium vivax gametocyte surface protein involved in the parasite fertilization process. Previous studies showed that Pvs48/45 proteins expressed in Escherichia coli (E. coli) and Chinese hamster ovary (CHO) cells were highly immunoreactive with sera from malaria-endemic areas and highly immunogenic in animal models. Here the immunogenicity in mice of three different vaccine formulations was compared. METHODS: Recombinant (r) Pvs48/45 proteins were expressed in E. coli and CHO, purified, formulated in Alhydrogel, GLA-SE and Montanide ISA-51 adjuvants and used to immunize BALB/c mice. Animals were immunized on days 0, 20 and 40, and serum samples were collected for serological analyses of specific antibody responses using ELISA and immunofluorescence (IFAT). Additionally, ex-vivo transmission-reducing activity (TRA) of sera on P. vivax gametocyte-infected human blood fed to Anopheles albimanus in direct membrane feeding assays (DMFA) was evaluated. RESULTS: Most immunized animals seroconverted after the first immunization, and some developed antibody peaks of 106 with all adjuvants. However, the three adjuvant formulations induced different antibody responses and TRA efficacy. While GLA-SE formulations of both proteins induced similar antibody profiles, Montanide ISA-51 formulations resulted in higher and longer-lasting antibody titers with CHO-rPvs48/45 than with the E. coli formulation. Although the CHO protein formulated in Alhydrogel generated a high initial antibody peak, antibody responses to both proteins rapidly waned. Likewise, anti-Pvs48/45 antibodies displayed differential recognition of the parasite proteins in IFAT and ex vivo blockade of parasite transmission to mosquitoes. The CHO-rPvs48/45 formulated in Montanide ISA-51 induced the most effective ex vivo parasite blockage. CONCLUSIONS: Three out of six vaccine formulations elicited antibodies with ex vivo TRA. The CHO-rPvs48/45 Montanide ISA-51 formulation induced the most stable antibody response, recognizing the native protein and the most robust ex vivo TRA. These results encourage further testing of the vaccine potential of this protein.
引用
- Arévalo-Herrera M, Miura K, Solano E, et al. Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice. Vaccine. 2021. PMID: 34802791. doi:10.1016/j.vaccine.2021.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。